

REMARKS

In the sequence listing, applicant has replaced <213> with the response “Artificial Sequence” so as to provide a valid response to this line in the sequence listing in accordance with §1.823 (b) of 37 C.F.R. The previous response, “Polypeptide sp.” was invalid as it neither provided the genus or species for the featured protein sequence, but also failed to label the sequence as “artificial” or “unknown.” The sequence of amino acids that applicant has utilized in the present invention were obtained by chemical synthesis practiced by many biotechnology laboratories.

Furthermore, in the sequence listing, applicant has added <220> in accordance with §1.823 (b) of 37 C.F.R. This line is a mandatory inclusion in any sequence listing where the response to <213> is “Artificial Sequence.” Applicant has responded “Chemically Synthesized” on <220> in compliance with the Examiner’s request and in affirmation of the source of the amino acid sequence disclosed, which was chemical synthesis, as described above.

Finally, applicant has amended the Computer Readable Form (C.R.F.) of the sequence listing to bring the invention into compliance with § 1.824 (a) (5) of 37 C.F.R., which requires page numbering not appear in the C.R.F. Thus, the page numbers have been removed.

CONCLUSION

For the foregoing reasons, Applicant requests reconsideration of the rejection.

Respectfully submitted,



Thomas A. O'Rourke

Reg. No.: 27,665

Bodner & O'Rourke, LLP

425 Broadhollow Road

Melville, NY 11747

CERTIFICATE OF MAILING

I hereby certify that the foregoing Response was mailed by first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on this 3rd day of October, 2006.



Thomas A. O'Rourke